Opinion|Videos|October 18, 2024
Challenges in Adopting Novel Therapies
Key Takeaways
- Translating clinical trial results to diverse patient populations is a significant challenge in real-world settings.
- Complex treatment regimens necessitate specialized infrastructure and training for healthcare providers.
Panelists discuss how implementing novel combination therapies or emerging agents from clinical trials into real-world clinical practice for multiple myeloma faces significant challenges, including managing complex dosing regimens, addressing potential toxicities, ensuring patient adherence, navigating insurance coverage and cost issues, and bridging the gap between highly controlled trial conditions and diverse patient populations encountered in everyday clinical settings
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the most significant challenges in implementing novel combination therapies or emerging agents from clinical trials into real-world clinical practice?
Advertisement
Related to this article
Infection prevention during bispecific antibody treatment requires pharmacists to coordinate baseline screening, antimicrobial prophylaxis, immunoglobulin monitoring, vaccination, and rapid evaluation of suspected infections.
For as long as practicing oncology pharmacists have been in the field, multiple myeloma carried a standard caveat: treatable, not curable—now that is changing.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
After 180 Years, Multiple Myeloma Gets a Definition of Cure
2
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
3
Severe Asthma's Effects May Extend Beyond the Lungs, Brain Imaging Study Suggests
4
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
5